Stocks in news: RIL, Adani Enterprises, Bajaj Housing, PB Fintech

Markets remained volatile on Monday but managed to recover a part of the steep Budget-day losses, ending nearly a percent higher. From a technical standpoint, analysts say the index’s ability to hold above the recent Budget-session lows and stage a rebound indicates a breather.

In today’s trade, shares of Bajaj Finance, RIL, Adani Enterprises, Bajaj Housing, PB Fintech among others will be in focus due to various news developments and third quarter results today.

Bajaj Finance, Adani Ports, Adani Enterprises, Varun Beverages
Shares of Bajaj Finance, Adani Ports, Adani Enterprises and Varun Beverages will be in focus as the companies will announce their third quarter results today.Bajaj Housing Finance
Bajaj Housing Finance reported a 21% jump in its December quarter net profit at Rs 665 crore compared to Rs 548 crore reported in the year ago period. The company’s net interest income (NII) stood at Rs 963 crore in Q3FY26, up 19% over Rs 806 crore posted in the corresponding period of the last financial year.

PB Fintech
PB Fintech’s quarterly profit more than ‍doubled as its digital insurance platform, Policybazaar, benefitted from ⁠higher demand for health and life insurance after last year’s tax cuts. The company on Monday also discussed ‌pursuing inorganic ‌growth opportunities through strategic investments and acquisitions and said ‌it would consider raising funds through a so-called qualified institutional placement of shares on February 5.
RIL
In an arbitration row between Reliance Industries (RIL) and the government over cost recovery provisions and reimbursement of royalties and taxes related to the Panna, Mukta and Tapti (PMT) gas fields, a division bench of the Delhi High Court on Monday rejected the objections raised by the Mukesh Ambani company over maintainability of the government’s appeal for enforcement of a 2016 final partial award (FPA) for its $3.86 billion claims against the company.

Eicher Motors
Mid-sized motorcycle maker Royal Enfield on Monday reported 14% jump in total sales at 1,04,322 units in January, as compared with 91,132 units in the same month last year. Domestic sales were at 93,781 units last month, as against 81,052 units in January 2025, up 16%.

Lupin
Drug firm Lupin said it has launched a generic cancer treatment medication in the US. The company has launched Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the US, following the approval from the US Food and Drug Administration (USFDA).